Local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients: Results of a randomized controlled trial.

Charlotte Hautefort,Alain Corré,Guillaume Poillon,Clément Jourdaine,Juliette Housset,Michael Eliezer,Benjamin Verillaud,Dorsaf Slama,Denis Ayache,Philippe Herman,Amélie Yavchitz,Jessica Guillaume,Camille Hervé, Wissame El Bakkouri,Dominique Salmon,Mary Daval

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases（2023）

引用 0|浏览5

暂无评分

摘要

In total, 123 patients were included and randomized (EG: 62 vs CG: 61). Two patients from the EG met the primary endpoint with no statistical difference between the two groups (p=0.5). To our knowledge, this is the first study evaluating local budesonide for COVID-19 related hyposmia treatment even though previous trials were performed with other local corticosteroids. Local budesonide efficacy was not demonstrated for persistent hyposmia related to COVID-19.

查看译文

关键词

local budesonide therapy,persistent hyposmia,non-severe

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要